The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Charles River Laboratories International Inc

NYSE: CRL
Last

(U.S.) $88.05

Today's change+0.24 +0.27%
Updated February 24 4:02 PM EST. Delayed by at least 15 minutes.
 

Charles River Laboratories International Inc

NYSE: CRL
Last

(U.S.) $88.05

Today's change+0.24 +0.27%
Updated February 24 4:02 PM EST. Delayed by at least 15 minutes.

Charles River Laboratories International Inc up (U.S.)$0.24

Charles River Laboratories International Inc closed up Friday by (U.S.)$0.24 or 0.27% to (U.S.)$88.05. Shares have lost 0.51% over the last five days, but sit 1.71% below their 52-week high. This security has performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $87.65
  • Previous close(U.S.) $87.81
  • High(U.S.) $88.07
  • Low(U.S.) $87.06
  • Bid / Ask-- / --
  • YTD % change+15.57%
  • Volume292,732
  • Average volume (10-day)475,286
  • Average volume (1-month)417,967
  • Average volume (3-month)492,647
  • 52-week range(U.S.) $67.20 to (U.S.) $89.59
  • Beta1.02
  • Trailing P/E27.35×
  • P/E 1 year forward17.39×
  • Forward PEG1.45×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $3.22
Updated February 24 4:02 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+9.28%

Based on its net profit margin of 9.28%, Charles River Laboratories International Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX1.57%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 24, 201609/24/2016Jun 25, 201606/25/2016Mar 26, 201603/26/2016
Revenue467426434355
Total other revenue--------
Total revenue467426434355
Gross profit180156170141
Total cost of revenue287269264214
Total operating expense398367376303
Selling / general / administrative988610083
Research & development--------
Depreciation / amortization1212116
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income69595851
Interest income (expense), net non-operating-8-7-9-4
Gain (loss) on sale of assets--------
Other--------
Income before tax64535452
Income after tax45383638
Income tax, total18161914
Net income45383537
Total adjustments to net income--------
Net income before extra. items45373537
Minority interest-1000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items45373537
Inc. avail. to common incl. extra. items45383537
Diluted net income45383537
Dilution adjustment--------
Diluted weighted average shares48484848
Diluted EPS excluding extraordinary itemsvalue per share0.930.780.730.78
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share0.930.780.730.78